Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks another impor ...